JP2023547313A5 - - Google Patents

Info

Publication number
JP2023547313A5
JP2023547313A5 JP2023518033A JP2023518033A JP2023547313A5 JP 2023547313 A5 JP2023547313 A5 JP 2023547313A5 JP 2023518033 A JP2023518033 A JP 2023518033A JP 2023518033 A JP2023518033 A JP 2023518033A JP 2023547313 A5 JP2023547313 A5 JP 2023547313A5
Authority
JP
Japan
Application number
JP2023518033A
Other languages
Japanese (ja)
Other versions
JPWO2022061368A5 (https=
JP2023547313A (ja
JP7810446B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/071505 external-priority patent/WO2022061368A2/en
Publication of JP2023547313A publication Critical patent/JP2023547313A/ja
Publication of JPWO2022061368A5 publication Critical patent/JPWO2022061368A5/ja
Publication of JP2023547313A5 publication Critical patent/JP2023547313A5/ja
Application granted granted Critical
Publication of JP7810446B2 publication Critical patent/JP7810446B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023518033A 2020-09-17 2021-09-18 Herv-k抗体治療薬 Active JP7810446B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063080009P 2020-09-17 2020-09-17
PCT/US2021/071505 WO2022061368A2 (en) 2020-09-17 2021-09-18 Herv-k antibody therapeutics

Publications (4)

Publication Number Publication Date
JP2023547313A JP2023547313A (ja) 2023-11-10
JPWO2022061368A5 JPWO2022061368A5 (https=) 2024-10-03
JP2023547313A5 true JP2023547313A5 (https=) 2024-10-03
JP7810446B2 JP7810446B2 (ja) 2026-02-03

Family

ID=80776422

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2023518033A Active JP7810446B2 (ja) 2020-09-17 2021-09-18 Herv-k抗体治療薬
JP2024516706A Pending JP2024541175A (ja) 2020-09-17 2022-09-16 Herv-k抗体治療法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024516706A Pending JP2024541175A (ja) 2020-09-17 2022-09-16 Herv-k抗体治療法

Country Status (6)

Country Link
US (2) US20240059787A1 (https=)
EP (2) EP4213881A4 (https=)
JP (2) JP7810446B2 (https=)
CN (2) CN116457018A (https=)
CA (1) CA3195886A1 (https=)
WO (2) WO2022061368A2 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024148216A2 (en) * 2023-01-05 2024-07-11 Neximmune, Inc. Combination therapy with t cell engager
WO2025222129A2 (en) * 2024-04-19 2025-10-23 Mozart Therapeutics, Inc. Engineered cytokines and targeted cytokine delivery

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060275747A1 (en) * 2001-12-07 2006-12-07 Hardy Stephen F Endogenous retrovirus up-regulated in prostate cancer
US20090297530A1 (en) * 2006-05-22 2009-12-03 Feng Wang-Johanning Herv-k antigens, antibodies, and methods
US20080019979A1 (en) * 2006-05-22 2008-01-24 Feng Wang-Johanning HERV-K Antigens, Antibodies, and Methods
US20110091544A1 (en) 2009-10-16 2011-04-21 Acelrx Pharmaceuticals, Inc. Compositions and Methods for Mild Sedation, Anxiolysis and Analgesia in the Procedural Setting
TWI487537B (zh) * 2010-06-09 2015-06-11 Nat Health Research Institutes 對抗腸病毒71型之單株抗體及其用途
US20140121123A1 (en) * 2010-10-29 2014-05-01 Kevin Caili Wang Methods for diversifying antibodies, antibodies derived therefrom and uses thereof
EP3783098A1 (en) * 2013-05-14 2021-02-24 Board Of Regents, The University Of Texas System Human application of engineered chimeric antigen receptor (car) t-cells
CA2927022C (en) 2013-10-11 2018-08-21 Asana Biosciences, Llc Protein-polymer-drug conjugates
US12016882B2 (en) * 2017-11-22 2024-06-25 The Brigham And Women's Hospital, Inc. Method of treating glioblastoma multiforme
KR20210087938A (ko) * 2018-09-28 2021-07-13 이미지냅 인코포레이티드 Cd8 이미징 구조체 및 이의 사용 방법
US20250145693A1 (en) * 2021-09-18 2025-05-08 Sunnybay Biotech, Inc. Herv-k antibody, cell, vaccine, and drug therapeutics

Similar Documents

Publication Publication Date Title
BR112023005462A2 (https=)
BR112023012656A2 (https=)
CL2025004052A1 (es) Derivados pirazolo[3,2-c]piridinona, inhibidores egfr y/o her2; composición; uso en cáncer
BR112021014123A2 (https=)
BR112023009656A2 (https=)
BR112022009896A2 (https=)
BR112021017747A2 (https=)
BR112022024743A2 (https=)
BR112022026905A2 (https=)
JP2023547313A5 (https=)
BR112023011738A2 (https=)
BR112023004146A2 (https=)
BR112023006729A2 (https=)
BR102021007058A2 (https=)
BR102020022030A2 (https=)
BR112023016292A2 (https=)
BR112023011610A2 (https=)
BR112023011539A2 (https=)
BR112023008976A2 (https=)
BR102021020147A2 (https=)
BR102021015566A2 (https=)
BR102021012230A2 (https=)
BR102021012003A2 (https=)
BR102021012107A2 (https=)
BR112021013417A2 (https=)